Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ocuphire Pharma Inc OCUP

Healthcare
Ocuphire Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. The Company’s lead retinal product candidate, APX3330, is a small-molecule inhibitor of Ref-1 (reduction oxidation effector factor-1 protein). Ref1 is a regulator of transcription factors such as HIF-1a... see more

Recent & Breaking News (NDAQ:OCUP)

Mid-Afternoon Market Update: Vicor Climbs After Q3 Results; Revolution Lighting Technologies Shares Slide

Benzinga.com  October 17, 2018

36 Stocks Moving In Wednesday's Mid-Day Session

Benzinga.com  October 17, 2018

Mid-Day Market Update: Crude Oil Down 2.7%; vTv Therapeutics Shares Spike Higher

Benzinga.com  October 17, 2018

Rexahn Announces $7.5 Million Registered Direct Offering

GlobeNewswire October 17, 2018

Rexahn Pharmaceuticals Presents Preliminary Safety and Efficacy Data From Ongoing Phase 2a Clinical Trial of RX-3117 in Combination With Abraxane® in Patients Newly Diagnosed With Metastatic Pancreatic Cancer

GlobeNewswire October 2, 2018

Rexahn Pharmaceuticals to Present at the 5th NCI Pancreatic Cancer Symposium

GlobeNewswire September 18, 2018

Rexahn Pharmaceuticals to Present at the 20th Annual Rodman & Renshaw Global Investment Conference

GlobeNewswire August 30, 2018

Rexahn Pharmaceuticals Announces Clinical Collaboration with Merck to Evaluate RX-5902 (Supinoxin™) in combination with KEYTRUDA® (pembrolizumab) for Triple Negative Breast Cancer

GlobeNewswire August 21, 2018

Rexahn Issues Mid-Year Shareholder Letter to Review Recent Progress and Clinical Plans

GlobeNewswire August 7, 2018

Rexahn Reports Second Quarter 2018 Financial Results

GlobeNewswire August 6, 2018

Rexahn Announces Adjournment of Annual Meeting of Shareholders until Wednesday, June 27, 2018

GlobeNewswire June 14, 2018

Rexahn Pharmaceuticals Announces Presentations at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting

GlobeNewswire June 4, 2018

Rexahn Phase 2a Combination Study of RX-3117 and Abraxane® in First-line Metastatic Pancreatic Cancer Patients Advances to Second Stage

GlobeNewswire May 15, 2018

Rexahn Reports First Quarter 2018 Financial Results

GlobeNewswire May 7, 2018

Analysis: Positioning to Benefit within PTC, Black Hills, Mack-Cali Realty, Milacron, Rexahn Pharmaceuticals, and Sunoco LP — Research Highlights Growth, Revenue, and Consolidated Results

GlobeNewswire May 3, 2018

Research Report Identifies Westinghouse Air Brake Technologies, National Western Life Group, Impinj, Ingles Markets, RCI Hospitality, and Rexahn Pharmaceuticals with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

GlobeNewswire March 22, 2018

Rexahn Pharmaceuticals to Present at Two Upcoming Conferences

GlobeNewswire March 13, 2018

Rexahn Pharmaceuticals Reports Full Year 2017 Financial Results

GlobeNewswire March 12, 2018

Rexahn Pharmaceuticals Announces Collaboration with Zhejiang Haichang Biotechnology Co., Ltd. for the Development of RX-0201 (Archexin®) for the treatment of Hepatocellular Carcinoma

GlobeNewswire February 8, 2018

Rexahn Pharmaceuticals to Present at the American Society of Clinical Oncology Genitourinary Cancers (ASCO GU) 2018 Annual Meeting

GlobeNewswire February 5, 2018